玻璃体腔注射康柏西普与雷珠单抗联合青光眼引流阀植入治疗新生血管性青光眼疗效比较

目的比较玻璃体腔注射康柏西普与雷珠单抗联合青光眼引流阀(AGV)植入治疗新生血管性青光眼(NVG)的效果。方法选择2017年1月-2018年1月广东省河源市源城区人民医院眼耳鼻咽喉科收治的NVG患者70例,依据其AGV植入术前玻璃体腔注射药物不同分成观察组和对照组各35例,观察组AGV植入术前玻璃体腔注射雷珠单抗,对照组则注射康柏西普,对比2组患者虹膜形成新生血管(NV)消退情况、手术总成功率及并发症发生情况。结果观察组经治疗后,共31只眼(88.57%)术后2~7 d房角及巩膜NV全部消退,4只眼(11.43%)房角及巩膜NV部分消退。对照组经治疗后,共32只眼(91.43%)术后2~7 d房角及巩膜NV全部消退,3只眼(8.57%)房角及巩膜有少许残留NV,并明显萎缩。2组患者术后不同时期的手术总成功率比较差异无统计学意义(P>0.05)。2组患者各项并发症发生率比较差异无统计学意义(P>0.05)。结论玻璃体腔注射抗血管内皮生长因子(VEGF)药物联合AGV植入手术治疗NVG安全有效,手术成功率较高,并发症较少,值得临床借鉴推广。

Comparison of therapeutic effects of intravitreal injection of compaq and lucentis combined with Ahmed glaucoma valve implantation for neovascular glaucoma

Objective To compare the effect of intravitreal injection of compaq and lucentis combined with ahmed glaucoma valve(AGV)implantation in the treatment of neovascular glaucoma(NVG).Methods From January 2017 to January 2018,70 patients with NVG admitted to the Department of Otolaryngology,Yuancheng District People’s Hospital,Heyuan City,Guangdong Province were selected and divided into observation group and control group according to different intravitreal injection drugs before AGV implantation.The observation group was injected with lucentis before AGV implantation,while the control group was injected with Compaq.The regression of iris neovascularization(NV),total success rate of operation and complications of the two groups were compared.Results After treatment,31 eyes(88.57%)in the observation group had complete regression of anterior chamber angle and scleral NV 2~7 days after operation,while 4 eyes(11.43%)had partial regression of anterior chamber angle and scleral NV.After treatment,32 eyes(91.43%)in the control group completely disappeared NV in the angle and sclera 2~7 days after operation,and 3 eyes(8.57%)had a little residual NV in the angle and sclera,which was obviously atrophic.There was no significant difference in the total success rate of the two groups at different postoperative periods(P>0.05).There was no significant difference in the incidence of complications between the two groups(P>0.05).Conclusion Intravitreal injection of anti-vascular endothelial growth factor(VEGF)drugs combined with AGV implantation is safe and effective in the treatment of NVG,with high success rate and fewer complications,which is worthy of clinical reference and promotion.